CRDP Practice Test

Certifications > CRDP > Practice Test

CRDP Practice Test (V1)

Dive into practice questions

Question 1

What is the primary purpose of the Orphan Drug Act of 1983?

  1. To mandate that all pharmacies stock medications for rare diseases.
  2. To provide financial incentives (e.g., tax credits, market exclusivity) to encourage the development of drugs for diseases affecting small populations.
  3. To establish a national registry for all patients with rare diseases.
  4. To fast-track the FDA approval process for all new medications.

Question 2

A pharmacist is coordinating the first fill for a patient starting on a newly approved gene therapy for a rare neuromuscular disorder, with a price tag of over $2 million. Which of the following is the MOST critical initial step?

  1. Counseling the patient on common side effects like headache and nausea.
  2. Ensuring the pharmacy’s refrigerator is at the correct temperature.
  3. Verifying insurance approval, patient assistance program enrollment, and the logistical plan for administration at a specialized center.
  4. Scheduling the patient’s next follow-up appointment in 6 months.

Question 3

What is the primary role of a pharmacist in interpreting a pharmacogenomic (PGx) test report for a patient with a rare metabolic disorder?

  1. To definitively diagnose the specific rare disease based on the genetic markers.
  2. To recommend lifestyle changes like diet and exercise.
  3. To correlate the patient’s genetic variants with the potential efficacy or toxicity of specific medications and adjust therapy accordingly.
  4. To order additional genetic tests to confirm the findings.

Question 4

A patient with a newly diagnosed ultra-rare disease feels isolated and is seeking information. A Certified Rare Disease Pharmacist would most appropriately connect this patient with which resource?

  1. The drug manufacturer’s sales representative.
  2. A large, general health-focused social media group.
  3. A disease-specific patient advocacy organization (e.g., NORD – National Organization for Rare Disorders).
  4. The hospital’s billing department.

Answer Key

  • Question 1: B. To provide financial incentives (e.g., tax credits, market exclusivity) to encourage the development of drugs for diseases affecting small populations. (The Act was specifically designed to make it financially viable for companies to develop treatments for conditions that affect a small number of people.)
  • Question 2: C. Verifying insurance approval, patient assistance program enrollment, and the logistical plan for administration at a specialized center. (For ultra-expensive, complex therapies, securing financial coverage and coordinating complex logistics are the absolute first hurdles to overcome before the medication can be dispensed.)
  • Question 3: C. To correlate the patient’s genetic variants with the potential efficacy or toxicity of specific medications and adjust therapy accordingly. (This is the core function of pharmacogenomics in practice – using genetic information to optimize drug selection and dosing. Diagnosis is the role of a physician.)
  • Question 4: C. A disease-specific patient advocacy organization (e.g., NORD – National Organization for Rare Disorders). (Patient advocacy organizations are crucial resources for patients with rare diseases, providing support, education, and connection to a community with shared experiences.)